Mortality and cause of death in mucopolysaccharidosis type II - A historical review based on data from the Hunter Outcome Survey (HOS)

Journal of Inherited Metabolic Disease

Volumn 32, Issue 4, 2009, Pages 534-543

  Jones, Simon A ^a   Almassy Z ^b   Beck, M ^c   Burt, K ^a   Clarke, J T ^d   Giugliani, R ^e   Hendriksz, C ^f   Kroepfl, T ^g   Lavery, L ^h   Lin, S P ⁱ   Malm, G ^j   Ramaswami, U ^k   Tincheva, R ^l   Wraith, J E ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b HEIM PÁL CHILDREN S HOSPITAL   (Hungary)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^f BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^g UNIVERSITY HOSPITAL GRAZ   (Austria)

^h MPS Society   (United Kingdom)

ⁱ MACKAY MEMORIAL HOSPITAL   (Taiwan)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^k ADDENBROOKE S HOSPITAL   (United Kingdom)

^l University Paediatric Hospital   (Bulgaria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IDURONATE 2 SULFATASE;

CARPAL TUNNEL SYNDROME; CAUSE OF DEATH; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DISEASE SEVERITY; ENZYME REPLACEMENT; HEARING LOSS; HEPATOMEGALY; HUMAN; HUNTER SYNDROME; LIFE EXPECTANCY; MORTALITY; REVIEW; SEIZURE; SLEEP APNEA SYNDROME; SPLENOMEGALY; SYMPTOMATOLOGY; VALVULAR HEART DISEASE;

ADOLESCENT; ADULT; AGE FACTORS; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DATA COLLECTION; FEMALE; HUMANS; IDURONATE SULFATASE; INFANT; MALE; MUCOPOLYSACCHARIDOSIS II; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 69449091683     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-009-1119-7     Document Type: Review

References (23)

1. Baehner F, Schmiedeskamp C, Krummenauer F, et al (2005) Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 28:1011-1017. doi: 10.1007/s10545-005-0112-z
2. Beck M, Ricci R, Widmer U, et al (2004) Fabry disease: Overall effects of agalsidase alfa treatment. Eur J Clin Invest 34:838-844. doi: 10.1111/ j.1365-2362.2004.01424.x
3. Cudry S, Tigaud I, Froissart R, Bonnet V, Maire I, Bozon D (2000) MPS II in females: Molecular basis of two different cases. J Med Genet 37:E29. doi: 10.1136/jmg.37.10.e29
4. Eng CM, Fletcher J, Wilcox WR, et al (2007) Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 30:184-192. doi: 10.1007/ s10545-007-0521-2
5. Hopkin RJ, Bissler J, Banikazemi M, et al (2008) Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 64:550-5.
6. Hunter C (1917) A rare disease in two brothers. Proc R Soc Med 10(Sect Study Dis Child):104-116.
7. Ligthelm RJ, Borzi V, Gumprecht J, Kawamori R, Wenying Y, Valensi P (2007) Importance of observational studies in clinical practice. Clin Ther 29(Spec No):1284-1292.
8. Morehead JM, Parsons DS (1993) Tracheobronchomalacia in Hunter's syndrome. Int J Pediatr Otorhinolaryngol 26:255-261. doi: 10.1016/ 0165-5876(93)90096-L
9. Muenzer J, Wraith JE, Beck M, et al (2006) A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8:465-473. doi: 10.1097/ 01.gim.0000232477.37660.fb
10. Neufeld EF, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 3421-52.
11. Pastores GM, Arn P, Beck M, et al (2007) The MPS I registry: Design, methodology, and early findings of a global disease registry for monitoring patients with mucopolysaccharidosis type I. Mol Genet Metab 91:37-47. doi: 10.1016/j.ymgme.2007.01.011
12. Poorthuis BJ, Wevers RA, Kleijer WJ, et al (1999) The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105:151-6.
13. Ramaswami U, Whybra C, Parini R, et al (2006) Clinical manifestations of Fabry disease in children: Data from the Fabry Outcome Survey. Acta Paediatr 95:86-92.doi: 10.1080/08035250500275022
14. Ries M, Clarke JT, Whybra C, et al (2006) Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 118:924-32. doi: 10.1542/peds.2005-2895
15. Schwarting A, Dehout F, Feriozzi S, Beck M, Mehta A, Sunder-Plassmann G (2006) Enzyme replacement therapy and renal function in 201 patients with Fabry disease. Clin Nephrol 66:77-84.
16. Thadhani R (2006) Formal trials versus observational studies. In Mehta A, Beck M, Sunder-Plassmann G, eds. Fabry disease: Perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis, 139-44.
17. Tuschl K, Gal A, Paschke E, Kircher S, Bodamer OA (2005) Mucopolysaccharidosis type II in females: Case report and review of literature. Pediatr Neurol 32:270-2. doi: 10.1016/ j.pediatrneurol.2004.10.009
18. Vellodi A, Young E, Cooper A, Lidchi V, Winchester B, Wraith JE (1999) Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis 22:638-48. doi: 10.1023/A:1005525931994
19. Vellodi A, Wraith JE, Cleary M, Ramaswami U, Lavery C, Jessop E (2007) Guidelines for the investigation and management of patients with mucopolysaccharidosis type II. http://www.ncg.nhs.uk/documents/ lsd_guidelines_for_mucopolysaccharidosis_type_II-120207.pdf. Gateway ID: 7848. Accessed November 2008
20. Wilcox WR, Oliveira JP, Hopkin RJ, et al (2008) Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry. Mol Genet Metab 93:112-28. doi: 10.1016/j.ymgme.2007.09.013
21. Wraith JE, Beck M, Giugliani R, Clarke J, Martin R, Muenzer J (2008a) Initial report from the Hunter Outcome Survey. Genet Med 10:508-16. doi: 10.1097/GIM.0b013e31817701e6
22. Wraith JE, Scarpa M, Beck M, et al (2008b) Mucopolysaccharidosis type II (Hunter syndrome): A clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 167:267-77. doi: 10.1007/s00431-007-0635-4
23. Young ID, Harper PS (1982) Mild form of Hunter's syndrome: Clinical delineation based on 31 cases. Arch Dis Child 57:828-36. doi: 10.1136/ adc.57.11.828